Denali Therapeutics Inc. (DNLI) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$19.71
Price Target
$34.50
Target Range
$25.00 — $40.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-6.6x
Forward PEG—
Implied Growth+9.6%
Median Target$36.00
Analyst Spread43.5%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$25
+26.8%
Consensus
$35
+75.0%
Bull Case
$40
+102.9%
DNLI Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Denali Therapeutics Inc. (DNLI) has a Wall Street consensus price target of $34.50, based on estimates from 18 covering analysts. With the stock currently trading at $19.71, this represents a potential upside of +75.0%. The company has a market capitalization of $3.08B.
Analyst price targets range from a low of $25.00 to a high of $40.00, representing a 43% spread in expectations. The median target of $36.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 18 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, DNLI trades at a trailing P/E of -6.6x. Analysts expect EPS to grow +9.6% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+39.0%
Avg Forward P/E30.1x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PRAXPraxis Precision Medicines, Inc. | $9.6B | $333.28 | $544.40 | +63.3% | Buy | — | 16 |
 ARVNArvinas, Inc. | $652M | $10.19 | $13.00 | +27.6% | Buy | — | 26 |
 RCUSArcus Biosciences, Inc. | $2.5B | $24.80 | $30.00 | +21.0% | Buy | — | 18 |
 KYMRKymera Therapeutics, Inc. | $6.9B | $84.63 | $117.06 | +38.3% | Buy | — | 26 |
 PTGXProtagonist Therapeutics, Inc. | $6.4B | $98.85 | $116.75 | +18.1% | Buy | 30.6x | 26 |
 ACADACADIA Pharmaceuticals Inc. | $3.9B | $22.57 | $34.78 | +54.1% | Buy | 50.9x | 37 |
 BIIBBiogen Inc. | $28.3B | $191.38 | $211.42 | +10.5% | Buy | 13.0x | 48 |
 IONSIonis Pharmaceuticals, Inc. | $12.6B | $76.02 | $107.27 | +41.1% | Buy | — | 32 |
 ALNYAlnylam Pharmaceuticals, Inc. | $39.5B | $295.91 | $445.67 | +50.6% | Buy | 44.2x | 52 |
 INVAInnoviva, Inc. | $1.9B | $22.80 | $37.67 | +65.2% | Buy | 11.9x | 10 |
Upside Potential Comparison
INVAPRAXACADALNYIONSKYMRARVNRCUSSee DNLI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DNLI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DNLI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDNLI — Frequently Asked Questions
Quick answers to the most common questions about buying DNLI stock.
What is the DNLI stock price target for 2026?
The consensus Wall Street price target for DNLI is $34.5, representing 75.0% upside from the current price of $19.71. With 18 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is DNLI a buy, sell, or hold?
DNLI has a consensus rating of "Buy" based on 18 Wall Street analysts. The rating breakdown is predominantly bullish, with 18 Buy/Strong Buy ratings. The consensus 12-month price target of $34.5 implies 75.0% upside from current levels.
Is DNLI stock overvalued or undervalued?
DNLI's current price is $19.71 with a consensus target of $34.5 (75.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can DNLI stock go?
The most bullish Wall Street analyst has a price target of $40 for DNLI, while the most conservative target is $25. The consensus of $34.5 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover DNLI stock?
DNLI is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 18 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the DNLI stock forecast?
The 12-month DNLI stock forecast based on 18 Wall Street analysts shows a consensus price target of $34.5, with estimates ranging from $25 (bear case) to $40 (bull case). The median consensus rating is "Buy".
Should I buy DNLI stock?
Wall Street analysts are very optimistic on DNLI, with a "Buy" consensus rating and $34.5 price target (75.0% upside). 18 of 18 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do DNLI price targets vary so much?
DNLI analyst price targets range from $25 to $40, a 43% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $34.5 consensus represents the middle ground.